Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH
Key Highlights
- ➤13 RWE abstracts will assess Rezdiffra treatment patterns across thousands of patients
- ➤Largest RWE dataset spans more than 12,000 Rezdiffra-treated patients
- ➤Rezdiffra will feature in more AASLD abstracts than any other MASH therapy
- ➤91% on Rezdiffra 100mg improved or stabilized liver stiffness at one year
- ➤Madrigal will present data on biomarkers, cardiovascular risk and patient outcomes
Expert Statements
David Soergel, M.D., Chief Medical Officer of Madrigal
“Rezdiffra established a new treatment era in MASH, and as more patients are being diagnosed and treated, real-world evidence is essential to understanding how treatment is working outside the clinical trial setting.”
David Soergel, M.D., Chief Medical Officer of Madrigal
“The breadth of research being presented at AASLD provides a robust and consistent picture of how patients are responding to Rezdiffra in the real world, including improvements in key noninvasive measures of liver health through 12 months.”
David Soergel, M.D., Chief Medical Officer of Madrigal
“The observations from multiple independent datasets across thousands of treated patients reinforce Rezdiffra as a foundational treatment for MASH, and reflect our commitment to generating rigorous post-approval evidence to advance the field.”
* Rezdiffra(®) (resmetirom) to be featured in more abstracts than any other approved or investigational MASH therapy * Real-world evidence abstracts examine Rezdiffra effectiveness, tolerability and treatment persistence in clinical practice; largest dataset spans more than 12,000 patients * Clinical abstracts further characterize the positive effects of Rezdiffra on noninvasive measures of treatment response, cardiovascular risk markers and patient-reported outcomes CONSHOHOCKEN, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that new clinical and real-world evidence (RWE) evaluating Rezdiffra and its growing impact on patient care will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting(®), taking place Nov. 5-9 in Denver.
Get started
Create a free account to read the full story.